ストックスクリーナーアプリを入手
4.39
6.20%
-0.29
プレマーケット:
4.39
前日終値:
$4.68
開ける：
$4.8
24時間の取引高:
34,804
Relative Volume:
0.22
時価総額：
$227.76M
収益：
$264.74M
当期純損益:
$-49.71M
株価収益率:
-1.0718
EPS:
-4.0959
ネットキャッシュフロー:
$-43.55M
1週間 パフォーマンス:
+22.28%
1か月 パフォーマンス:
-27.32%
6か月 パフォーマンス:
+218.12%
1年 パフォーマンス:
-1.79%
1日の値動き範囲:
$4.39
$4.80
1週間の範囲:
$3.585
$4.8486
52週間の値動き範囲:
$1.305
$7.305
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
名前
Camp 4 Therapeutics Corp
セクター
電話
617-651-8867
住所
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.39 | 242.80M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-16 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-05-27 | 開始されました | Wedbush | Outperform |
| 2024-11-05 | 開始されました | JP Morgan | Overweight |
| 2024-11-05 | 開始されました | Piper Sandler | Overweight |
| 2024-11-05 | 開始されました | William Blair | Outperform |
| 2022-08-16 | アップグレード | Craig Hallum | Hold → Buy |
| 2021-12-22 | ダウングレード | Craig Hallum | Buy → Hold |
| 2021-09-24 | 繰り返されました | Craig Hallum | Buy |
| 2021-06-25 | 繰り返されました | Craig Hallum | Buy |
| 2020-12-18 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-04-17 | アップグレード | Jefferies | Hold → Buy |
| 2020-03-05 | 繰り返されました | Craig Hallum | Buy |
| 2019-12-20 | 繰り返されました | Craig Hallum | Buy |
| 2019-12-20 | ダウングレード | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-01 | 繰り返されました | Craig Hallum | Buy |
| 2019-03-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-01-25 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-12-21 | アップグレード | Craig Hallum | Hold → Buy |
| 2018-12-14 | 繰り返されました | B. Riley FBR | Buy |
| 2018-12-11 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | 開始されました | Goldman | Neutral |
| 2018-10-15 | 開始されました | Jefferies | Hold |
| 2018-09-28 | 繰り返されました | Craig Hallum | Hold |
| 2018-04-27 | 繰り返されました | Craig Hallum | Hold |
| 2018-03-08 | ダウングレード | Craig Hallum | Buy → Hold |
| 2018-02-16 | アップグレード | First Analysis Sec | Equal-Weight → Overweight |
すべてを表示
Camp 4 Therapeutics Corp (CAMP) 最新ニュース
FMR LLC Increases Stake in Camp4 Therapeutics Corp: A Strategic Move in Biotechnology - GuruFocus
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
Downgrade Watch: Can Camp4 Therapeutics Corporation ride the EV waveTrade Analysis Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Will Camp4 Therapeutics Corporation benefit from rising consumer demand2025 Sector Review & Verified Momentum Stock Alerts - mfd.ru
Analysis Recap: Will Camp4 Therapeutics Corporation outperform the market in YEAR2025 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
Retail Trends: Is CVD Equipment Corporation stock undervalued right nowExit Point & Low Volatility Stock Recommendations - baoquankhu1.vn
Market Outlook: Will Camp4 Therapeutics Corporation stock benefit from M AJuly 2025 Final Week & Growth Focused Stock Pick Reports - baoquankhu1.vn
CAMP4 Therapeutics announces $28 million common stock offering - MSN
Signal Recap: Will Camp4 Therapeutics Corporation outperform the market in YEARMarket Growth Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
New CAMP4 hire receives option to buy 8,000 shares at $5.78 each in grant - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why - sharewise.com
Published on: 2026-01-10 23:34:38 - ulpravda.ru
CAMP4 Therapeutics updates corporate investor presentation materials - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Scrip Asks... What Does 2026 Hold For Biopharma? Part 1: Capital Allocation And Dealmaking - Citeline News & Insights
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR) - The Globe and Mail
Stock Recap: What hedge fund activity signals for Camp4 Therapeutics Corporation stockMarket Performance Report & Verified Technical Signals - Улправда
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Wedbush Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation - MSN
Insilico’s big gain after Hong Kong listing: Finance Report - biocentury.com
Sanofi adds HBV vaccine, shingles candidate via Dynavax takeout: Deals Report - BioCentury
Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER) - The Globe and Mail
Camp4 Therapeutics signs new Watertown lease, accelerates Cambridge exit By Investing.com - Investing.com South Africa
Camp4 Therapeutics signs new Watertown lease, accelerates Cambridge exit - Investing.com
CAMP4 Therapeutics Restructures Leases and Expands Facilities - TipRanks
Deal Watch: Boehringer Signs On For Rectify’s Chronic Kidney Disease Assets - Citeline News & Insights
Is Camp4 Therapeutics Corporation a good long term investmentMarket Timing Techniques & Superior Capital Trading - earlytimes.in
Will Camp4 Therapeutics Corporation stock benefit from green energy trends2025 Technical Overview & Real-Time Buy Signal Notifications - Улправда
How Camp4 Therapeutics Corporation stock valuations compare to rivals2025 Sector Review & Real-Time Volume Triggers - Улправда
Market Rankings: How Camp4 Therapeutics Corporation stock performs in rate cut cyclesWeekly Trade Recap & Community Trade Idea Sharing - Улправда
Will Camp4 Therapeutics Corporation stock deliver better than expected guidanceTrade Entry Report & Long-Term Safe Investment Ideas - Улправда
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst - Benzinga
Quarterly Recap: Will Camp4 Therapeutics Corporation stock outperform international peersJuly 2025 Chart Watch & Detailed Earnings Play Alerts - Улправда
How Camp4 Therapeutics Corporation stock performs in rate cut cyclesJuly 2025 Update & Weekly High Momentum Picks - Улправда
CAMP4 Therapeutics (Nasdaq:CAMP) Enters Research and License Agreement with GSK - Kalkine Media
CAMP4 Therapeutics Announces $28 Million Common Stock Offering - TipRanks
CAMP4 Therapeutics (CAMP) to raise about $28M in 5M-share equity deal - Stock Titan
Will Camp4 Therapeutics Corporation stock outperform international peersGap Down & Advanced Technical Analysis Signals - Улправда
CAMP4 Therapeutics and GSK partner on ASO development for diseases By Investing.com - Investing.com Nigeria
CAMP4 Therapeutics prices $30 million common stock offering By Investing.com - Investing.com Nigeria
CAMP4 and GSK enter strategic collaboration to advance RNA-based therapeutic discoveries - PharmaLive
CAMP4, GSK form RNA therapeutics collaboration agreement - TipRanks
CAMP4 Therapeutics prices $30 million common stock offering - Investing.com India
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock - The Manila Times
CAMP4 Therapeutics and GSK partner on ASO development for diseases - Investing.com
Camp 4 Therapeutics Corp (CAMP) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):